SCHEMBL21114902

SCHEMBL21114902

COC(=O)C1(C)CC(=O)C(C)(C(=O)OC)CC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
NPSR1 Q6W5P4 3/20 0.34
KDM4E B2RXH2 6/20 0.33
LMNA P02545 3/20 0.33
GAA P10253 3/20 0.33
POLB P06746 3/20 0.33
MAPT P10636 3/20 0.33
ALDH1A1 P00352 4/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
CYP1A2 P05177 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HTT P42858 2/20 0.32
EED O75530 1/20 0.31
SUZ12 Q15022 1/20 0.31
EZH2 Q15910 1/20 0.31
HIF1A Q16665 1/20 0.31
EPAS1 Q99814 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26383029 0.92 SMN1; SMN2 (0.35) SMN1; SMN2KMT2AMEN1NPSR1KDM4E
SCHEMBL10046851 0.74 EED (0.42) SMN1; SMN2KMT2AMEN1NPSR1MAPT
SCHEMBL5352623 0.74 EED (0.42) SMN1; SMN2KMT2AMEN1NPSR1MAPT
SCHEMBL6902793 0.73 EED (0.41) SMN1; SMN2KMT2AMEN1NPSR1LMNA
SCHEMBL20424094 0.73 SMN1; SMN2 (0.34) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL7550154 0.73 NPSR1 (0.41) SMN1; SMN2KMT2AMEN1NPSR1MAPT
SCHEMBL28218027 0.73 NPSR1 (0.41) SMN1; SMN2KMT2AMEN1NPSR1MAPT
SCHEMBL21114903 0.72 FFAR3 (0.39) SMN1; SMN2NPSR1KDM4ELMNAPOLB
SCHEMBL17317465 0.71 KMT2A (0.36) SMN1; SMN2KMT2AMEN1NPSR1KDM4E
SCHEMBL18101499 0.71 CYP3A4 (0.38) SMN1; SMN2KMT2AMEN1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634430-B1 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2024-08-07 EP disclosed
US-20240158567-A1 ALL-PURPOSE POLY(3-HYDROXYBUTYRATE) BY STEREOMICROSTRUCTURAL ENGINEERING UNITED STATES DEPARTMENT OF ENERGY 2024-05-16 US disclosed
US-20230312815-A1 SYNTHESIS OF POLYMERS FROM CYCLIC DIOLIDES COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2023-10-05 US disclosed
US-20230312815-A1 SYNTHESIS OF POLYMERS FROM CYCLIC DIOLIDES COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2023-10-05 US disclosed
US-20230293458-A1 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2023-09-21 US disclosed
US-11629223-B2 Synthesis of polymers from cyclic diolides COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2023-04-18 US disclosed
US-20210206912-A1 SYNTHESIS OF POLYMERS FROM CYCLIC DIOLIDES COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2021-07-08 US disclosed
US-20210206912-A1 SYNTHESIS OF POLYMERS FROM CYCLIC DIOLIDES COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2021-07-08 US disclosed
US-10954335-B2 Synthesis of crystalline polymers from cyclic diolides COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2021-03-23 US disclosed
US-10954335-B2 Synthesis of crystalline polymers from cyclic diolides COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2021-03-23 US disclosed
US-20200101030-A1 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME KINTAI THERAPEUTICS, INC. 2020-04-02 US disclosed
CN-110869024-A Multi-biological agents and methods of use thereof 旗舰创业创新五公司 2020-03-06 CN disclosed
US-20190211144-A1 SYNTHESIS OF CRYSTALLINE POLYMERS FROM CYCLIC DIOLIDES COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2019-07-11 US disclosed
US-20190211144-A1 SYNTHESIS OF CRYSTALLINE POLYMERS FROM CYCLIC DIOLIDES COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200101030-A1 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME SI, FABP2, CEL SMN1; SMN2 2598/4885KMT2A 1842/4885MEN1 2289/4885
US-20230293458-A1 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME SI, FABP2, CEL SMN1; SMN2 2598/4885KMT2A 1842/4885MEN1 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.